ESC Professional Premium Access

Renal failure and cardiovascular disease 2

Event: ESC Congress 2022
Topic: Renal Failure and Cardiovascular Disease
Session type: Moderated ePosters
Date: 26 August 2022
Time: 15:15 - 16:00

Congress Session

6 presentations in this session

Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial

Speaker: Doctor K. Mahaffey (Stanford, US)

Effects of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan: results from the phase 2 RESCUE-2 trial

Speaker: Ms A. Pettersson Meyer (DK)

CAD in kidney transplant recipients: a real-world assessment pre-ISCHEMIA-CKD

Speaker: Doctor B. Rocha (Lisbon, PT)

Epigenetic regulation of miR-181c-5p in a cardiorenal mouse model with co-occurring thrombotic microangiopathy

Speaker: Ms J. Boen (Antwerp, BE)

Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial

Speaker: Doctor A. Singh (Boston, US)

The difference in prognostic value between high-sensitive cardiac troponin T and I for long-term major adverse cardiovascular events in hemodialysis patients

Speaker: Associate Professor W. Wongcharoen (Chiang Mai, TH)

6 speakers from this session

Doctor Kenneth W Mahaffey

Stanford University School of Medicine, Stanford (United States of America)
0 follower

Ms Anna Sina Pettersson Meyer

, (Denmark)
0 follower

Doctor Bruno Rocha

Hospital Santa Cruz, Lisbon (Portugal)
0 follower

Ms Jente Ramona Angelica Boen

University of Antwerp, Antwerp (Belgium)
0 follower

Doctor Ajay Singh

Brigham And Women'S Hospital, Harvard Medical School, Boston (United States of America)
0 follower

Associate Professor Wanwarang Wongcharoen

Chiang Mai University, Chiang Mai (Thailand)
0 follower

This platform is supported by

logo Novo Nordisk